search
Back to results

AutoDx-DR Prospective Clinical Validation Study Protocol

Primary Purpose

Diabetic Retinopathy

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
AutoDX-DR
Sponsored by
Hill-Rom
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Diabetic Retinopathy focused on measuring Diabetic Retinopathy

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

A documented diagnosis of diabetes mellitus in accordance with the criteria established by the American Diabetes Association (ADA)7 as indicated by at least one of the following:

  • Hemoglobin A1c (HbA1c) > 6.5%
  • Fasting Plasma Glucose (FPG; period of fasting must be at least 8 hours) > 126 mg/dL (7.0 mmol/L)
  • Oral Glucose Tolerance Test (OGTT) with 2-hour plasma glucose >200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75 g anhydrous glucose dose dissolved in water o Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)

    • 22 years of age or older
    • Ability to understand the study and sign the informed consent

Exclusion Criteria:

  • A documented diagnosis of more than mild diabetic retinopathy in the patient record.

    o More than mild diabetic retinopathy shall be defined as moderate NPDR, severe NPDR, proliferative diabetic retinopathy (PDR) or any level of DME; or a documented diabetic eye exam report indicating more than microaneurysms [i.e. presence of intraretinal hemorrhages, venous beading, intraretinal microvascular abnormalities (IRMA,) neovascularization or DME.]

  • They report having severe vision loss in both eyes.
  • They report a history of laser treatment or surgery of the retina.
  • They report that they are currently receiving treatment for DR or DME.
  • They report a diagnosis of angle closure glaucoma.
  • They report hypersensitivity to light which makes retinal imaging uncomfortable.
  • They are currently pregnant or breastfeeding.
  • They report that they have an iris supported intraocular lens or anterior chamber intraocular lens associated with a previous cataract surgery.
  • They had a previous pupilloplasty surgery.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    AutoDX and Gold Standard

    Arm Description

    A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera

    Outcomes

    Primary Outcome Measures

    Sensitivity
    The ability of AutoDX-DR to correctly identify those with the disease (true positive rate)
    Specificity
    The ability of AutoDX-DR to correctly identify those without the disease (true negative rate)

    Secondary Outcome Measures

    Full Information

    First Posted
    November 9, 2020
    Last Updated
    November 12, 2020
    Sponsor
    Hill-Rom
    Collaborators
    Rho, Inc., ClinEdge
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04627272
    Brief Title
    AutoDx-DR Prospective Clinical Validation Study Protocol
    Official Title
    An Evaluation of the Accuracy of AutoDx-DR, a Software Algorithm That Detects Diabetic Retinopathy From Retinal Images of Individuals With Diabetes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 1, 2020 (Anticipated)
    Primary Completion Date
    July 31, 2021 (Anticipated)
    Study Completion Date
    July 31, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hill-Rom
    Collaborators
    Rho, Inc., ClinEdge

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    In this study, we will prospectively evaluate the accuracy of a deep-learning based software algorithm in the detection of diabetic retinopathy from 60° wide single-field retinal fundus images.
    Detailed Description
    We will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. AutoDx-DR will generate an initial Refer or Not Refer recommendation and the remote ophthalmologist will provide a detailed diagnostic image interpretation which will be used for patient management and referral during the course of the study. AutoDx-DR can also generate a third output which is "Inadequate for Interpretation". In this case, the images will still be sent to the remote ophthalmologist for interpretation. If the ophthalmologist also cannot interpret the images, the patient will be recommended to have an in-person comprehensive ophthalmologic exam. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera (i.e. Zeiss Cirrus 600 photo, or other appropriate FDA-cleared imaging device with stereo fundus photography and SD-OCT capability that meets the requirements of the certified fundus photography reading center such as Topcon, Optovue, and Heidelberg). The 4W and SD-OCT imaging will be performed by a certified technician located at or near the enrolling study site. The 4W and SD-OCT images will be interpreted by a certified fundus photography reading center (FPRC) for more than mild DR or any diabetic macular edema. The FPRC's Not Refer/Refer determination will be used as the "gold standard" interpretation in this study. The AutoDx-DR interpretation of the 60° wide single-field images will be compared to the FPRC "gold standard" interpretation for the Not Refer/Refer recommendation. Accuracy metrics of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR), with 95% confidence intervals will be calculated. All diabetic patients who are attending routine primary care or endocrinology appointments and meet the enrollment criteria will be invited to participate in the study. All study procedures will be performed during a single study visit.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetic Retinopathy
    Keywords
    Diabetic Retinopathy

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    This is a study to determine the accuracy of AutoDX. All eligible study participants will have a retinal fundus image taken which is then uploaded to the RetinaVue Network. Subjects will also undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera.
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    1539 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    AutoDX and Gold Standard
    Arm Type
    Experimental
    Arm Description
    A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera
    Intervention Type
    Device
    Intervention Name(s)
    AutoDX-DR
    Intervention Description
    AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
    Primary Outcome Measure Information:
    Title
    Sensitivity
    Description
    The ability of AutoDX-DR to correctly identify those with the disease (true positive rate)
    Time Frame
    Each subject will only have one day study visit and will provide the AutoDX-DR and gold standard reading during their one visit.
    Title
    Specificity
    Description
    The ability of AutoDX-DR to correctly identify those without the disease (true negative rate)
    Time Frame
    Each subject will only have one day study visit and will provide the AutoDX-DR and gold standard reading during their one visit.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    22 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A documented diagnosis of diabetes mellitus in accordance with the criteria established by the American Diabetes Association (ADA)7 as indicated by at least one of the following: Hemoglobin A1c (HbA1c) > 6.5% Fasting Plasma Glucose (FPG; period of fasting must be at least 8 hours) > 126 mg/dL (7.0 mmol/L) Oral Glucose Tolerance Test (OGTT) with 2-hour plasma glucose >200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75 g anhydrous glucose dose dissolved in water o Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L) 22 years of age or older Ability to understand the study and sign the informed consent Exclusion Criteria: A documented diagnosis of more than mild diabetic retinopathy in the patient record. o More than mild diabetic retinopathy shall be defined as moderate NPDR, severe NPDR, proliferative diabetic retinopathy (PDR) or any level of DME; or a documented diabetic eye exam report indicating more than microaneurysms [i.e. presence of intraretinal hemorrhages, venous beading, intraretinal microvascular abnormalities (IRMA,) neovascularization or DME.] They report having severe vision loss in both eyes. They report a history of laser treatment or surgery of the retina. They report that they are currently receiving treatment for DR or DME. They report a diagnosis of angle closure glaucoma. They report hypersensitivity to light which makes retinal imaging uncomfortable. They are currently pregnant or breastfeeding. They report that they have an iris supported intraocular lens or anterior chamber intraocular lens associated with a previous cataract surgery. They had a previous pupilloplasty surgery.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Elizabeth Downs
    Phone
    9893394131
    Email
    Elizabeth.Downs@hillrom.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Lindsay E Downing
    Phone
    8043070924
    Email
    lindsay.downing@hillrom.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Antonio Piñero-Piloña, MD
    Organizational Affiliation
    Diabetes Care Center
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Joseph Woolley, MD
    Organizational Affiliation
    Southwest Internal Medicine
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Keila Hoover, MD
    Organizational Affiliation
    Hoover Family Medicine
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Quang Vo, MD
    Organizational Affiliation
    Dr. Steven Barag, DO
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Peter Mattar, MD
    Organizational Affiliation
    Dr. Peter N. Mattar, MD
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Efrain Soto, MD
    Organizational Affiliation
    Park Lakes Family Medicine
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Harish Thakkar, MD
    Organizational Affiliation
    Southwest Medical Clinic
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Luis Gonzalez-Orozco, MD
    Organizational Affiliation
    Clinic of Luis Gonzalez
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Jennifer Bellucci-Jackson, MD
    Organizational Affiliation
    Family Medicine Specialists
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    AutoDx-DR Prospective Clinical Validation Study Protocol

    We'll reach out to this number within 24 hrs